The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

TNXP READ THE FULL TNXP RESEARCH REPORT Financial Update On July 25, 2025, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ...